Robert Hershberg - Celgene Chief Scientific Officer
Executive
Dr. Robert M. Hershberg MD PhD was promoted as Chief Scientific Officer of the Company He will lead the expansion of our scientific platforms and discovery capabilities. Rob joined Celgene in August 2014 and has led the development of our immunooncology efforts helping to engineer several key collaborations and partnerships. since 2016.
| Age | 49 |
| Tenure | 8 years |
| Phone | 908 673-9000 |
| Web | www.celgene.com |
Celgene Management Efficiency
The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jerry Canning | National CineMedia | N/A | |
| Lisa Sheehan | CarsalesCom Ltd ADR | N/A | |
| Michael Esq | Playtika Holding Corp | 53 | |
| James Rogers | Cars Inc | 67 | |
| Darlan Monterisi | Playtika Holding Corp | N/A | |
| Matthew Gold | Cars Inc | N/A | |
| Adam Johnson | National CineMedia | N/A | |
| Jo Allan | CarsalesCom Ltd ADR | N/A | |
| Gili Brudno | Playtika Holding Corp | 50 | |
| Jason Blackman | CarsalesCom Ltd ADR | N/A | |
| Nicole Birman | CarsalesCom Ltd ADR | N/A | |
| Jeanette Tomy | Cars Inc | 51 | |
| Kris Doyle | Visteon Corp | N/A | |
| Beyza Sarioglu | Visteon Corp | N/A | |
| Rick Butler | National CineMedia | N/A | |
| Amy Tunick | National CineMedia | N/A | |
| Stacie Tursi | National CineMedia | N/A | |
| Ted Watson | National CineMedia | N/A | |
| Colleen Myers | Visteon Corp | N/A | |
| Kellie Cordner | CarsalesCom Ltd ADR | N/A | |
| John Clavadetscher | Cars Inc | 43 | |
Management Performance
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 |
Celgene Leadership Team
Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Loughlin, Independent Director | ||
| Michael Friedman, Independent Director | ||
| Michael Bonney, Director | ||
| Hans Bishop, Director | ||
| John Weiland, Director | ||
| Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary | ||
| Gilla Kaplan, Independent Director | ||
| Patricia Hall, Director | ||
| Robert Hugin, Chairman of the Board and Presidentident, CEO | ||
| Peter Kellogg, CFO, Executive Vice President | ||
| David Elkins, Executive Vice President | ||
| Perry Karsen, CEO of Celgene Cellular Therapeutics | ||
| Rupert Vessey, President - Research and Early Development | ||
| Carrie Cox, Independent Director | ||
| Terrie Curran, President Global Inflammation & Immunology Franchise | ||
| Michael Pehl, President Hematology & Oncology | ||
| Mark Alles, President, COO and Director | ||
| Alise Reicin, President - Global Clinical Development | ||
| Jonathan Biller, Executive Vice President General Counsel | ||
| Julia Haller, Director | ||
| Robert Hershberg, Chief Scientific Officer | ||
| Jacqualyn Fouse, President of Global Hematology and Oncology and Director | ||
| Ernest Mario, Independent Director | ||
| Scott Smith, President - Inflammation & Immunology | ||
| Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development | ||
| Richard Barker, Independent Director | ||
| Michael Casey, Lead Independent Director |
Celgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Celgene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Celgene's short interest history, or implied volatility extrapolated from Celgene options trading.
Pair Trading with Celgene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Boston Scientific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boston Scientific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boston Scientific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boston Scientific Corp to buy it.
The correlation of Boston Scientific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boston Scientific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boston Scientific Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boston Scientific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |